Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients

Psychoneuroendocrinology

Volumn 64, Issue , 2016, Pages 108-116

  Sun, Hong Qiang ^a   Li, Su Xia ^b   Chen, Fang Bin ^c   Zhang, Yan ^c   Li, Peng ^a,c   Jin, Mei ^c   Sun, Yan ^b   Wang, Fan ^b   Mi, Wei Feng ^a   Shi, Le ^a,b   Yue, Jing li ^a   Yang, Fu De ^b   Lu, Lin ^a,b  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c Department of Pharmacy   (China)

Author keywords

Circadian rhythm; Clock genes; Clozapine; Hormones; Peptides; Schizophrenia

Indexed keywords

CLOZAPINE; HYDROCORTISONE; INSULIN; MESSENGER RNA; OREXIN; PER1 PROTEIN; PER2 PROTEIN; PER3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CLOCK; TRANSCRIPTION FACTOR NPAS2; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CIRCADIAN RHYTHM SIGNALING PROTEIN; NERVE PROTEIN; NPAS2 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; EVENING DOSAGE; GENE; GENE EXPRESSION; HEART DISEASE; HEMATOLOGIC DISEASE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; MAINTENANCE THERAPY; MALE; NEUROBIOLOGY; OREXIN BLOOD LEVEL; PER1 GENE; PER2 GENE; PER3 GENE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; CLOZAPINE; HUMANS; HYDROCORTISONE; INSULIN; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; OREXINS; PERIOD CIRCADIAN PROTEINS; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84951799850     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.11.013     Document Type: Article

References (56)

1. Advokat C. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain. Essent. Psychopharmacol. 2005, 6:73-90.
2. Ahlersova E., Ahlers I., Smajda B., Kassayova M. The effect of various photoperiods on daily oscillations of serum corticosterone and insulin in rats. Physiol. Res. 1992, 41:315-321.
3. American Psychiatric Association 1994. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Am Psychiatric Assoc Press: Washington DC.
4. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 2004, 65:1335-1342.
5. Aston C., Jiang L., Sokolov B.P. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J. Neurosci. Res. 2004, 77:858-866.
6. Baumann C.R., Bassetti C.L. Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. Sleep Med. Rev. 2005, 9:253-268.
7. Berman N., Chou H.F., Berman A., Ipp E. A mathematical model of oscillatory insulin secretion. Am. J. Physiol. 1993, 264:R839-851.
8. Chien Y.L., Liu C.M., Shan J.C., Lee H.J., Hsieh M.H., Hwu H.G., Chiou L.C. Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology 2015, 53:1-9.
9. Chouinard S., Poulin J., Stip E., Godbout R. Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2004, 30:957-967.
10. Date Y., Ueta Y., Yamashita H., Yamaguchi H., Matsukura S., Kangawa K., Sakurai T., Yanagisawa M., Nakazato M. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:748-753.
11. DeBruyne J.P., Weaver D.R., Reppert S.M. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat. Neurosci. 2007, 10:543-545.
12. Dudley C.A., Erbel-Sieler C., Estill S.J., Reick M., Franken P., Pitts S., McKnight S.L. Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice. Science 2003, 301:379-383.
13. Garner B., Phassouliotis C., Phillips L.J., Markulev C., Butselaar F., Bendall S., Yun Y., McGorry P.D. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J. Psychiatr. Res. 2011, 45:249-255.
14. Gonnissen H.K., Rutters F., Mazuy C., Martens E.A., Adam T.C., Westerterp-Plantenga M.S. Effect of a phase advance and phase delay of the 24-h cycle on energy metabolism, appetite, and related hormones. Am. J. Clin. Nutr. 2012, 96:689-697.
15. Haus E. Chronobiology in the endocrine system. Adv. Drug Deliv. Rev. 2007, 59:985-1014.
16. Horvath T.L., Peyron C., Diano S., Ivanov A., Aston-Jones G., Kilduff T.S., van Den Pol A.N. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J. Comp. Neurol. 1999, 415:145-159.
17. Johansson C., Willeit M., Smedh C., Ekholm J., Paunio T., Kieseppa T., Lichtermann D., Praschak-Rieder N., Neumeister A., Nilsson L.G., Kasper S., Peltonen L., Adolfsson R., Schalling M., Partonen T. Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. Neuropsychopharmacology 2003, 28:734-739.
18. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
20. Ko C.H., Takahashi J.S. Molecular components of the mammalian circadian clock. Hum. Mol. Genet. 2006, 15:R271-R277.
21. Lefebvre P.J., Paolisso G., Scheen A.J., Henquin J.C. Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. Diabetologia 1987, 30:443-452.
22. Leproult R., Holmback U., Van Cauter E. Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss. Diabetes 2014, 63:1860-1869.
23. Lewis S.W., Davies L., Jones P.B., Barnes T.R., Murray R.M., Kerwin R., Taylor D., Hayhurst K.P., Markwick A., Lloyd H., Dunn G. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol. Assess. 2006, 10:1-165. iii-iv, ix-xi.
24. Li S.X., Liu L.J., Jiang W.G., Lu L. Morphine withdrawal produces circadian rhythm alterations of clock genes in mesolimbic brain areas and peripheral blood mononuclear cells in rats. J. Neurochem. 2009, 109:1668-1679.
25. Li S.X., Shi J., Epstein D.H., Wang X., Zhang X.L., Bao Y.P., Zhang D., Zhang X.Y., Kosten T.R., Lu L. Circadian alteration in neurobiology during 30 days of abstinence in heroin users. Biol. Psychiatry 2009, 65:905-912.
26. Li S.X., Liu L.J., Jiang W.G., Sun L.L., Zhou S.J., Le Foll B., Zhang X.Y., Kosten T.R., Lu L. Circadian alteration in neurobiology during protracted opiate withdrawal in rats. J. Neurochem. 2010, 115:353-362.
27. Li S.X., Liu L.J., Xu L.Z., Gao L., Wang X.F., Zhang J.T., Lu L. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology 2013, 38:2789-2799.
28. Mann K., Rossbach W., Muller M.J., Muller-Siecheneder F., Pott T., Linde I., Dittmann R.W., Hiemke C. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006, 31:256-264.
29. Mansour H.A., Wood J., Logue T., Chowdari K.V., Dayal M., Kupfer D.J., Monk T.H., Devlin B., Nimgaonkar V.L. Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav. 2006, 5:150-157.
30. Mansour H.A., Talkowski M.E., Wood J., Chowdari K.V., McClain L., Prasad K., Montrose D., Fagiolini A., Friedman E.S., Allen M.H., Bowden C.L., Calabrese J., El-Mallakh R.S., Escamilla M., Faraone S.V., Fossey M.D., Gyulai L., Loftis J.M., Hauser P., Ketter T.A., Marangell L.B., Miklowitz D.J., Nierenberg A.A., Patel J., Sachs G.S., Sklar P., Smoller J.W., Laird N., Keshavan M., Thase M.E., Axelson D., Birmaher B., Lewis D., Monk T., Frank E., Kupfer D.J., Devlin B., Nimgaonkar V.L. Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord. 2009, 11:701-710.
31. Matsuda K.T., Cho M.C., Lin K.M., Smith M.W., Young A.S., Adams J.A. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol. Bull. 1996, 32:253-257.
32. Mazzoccoli G., Pazienza V., Vinciguerra M. Clock genes and clock-controlled genes in the regulation of metabolic rhythms. Chronobiol. Int. 2012, 29:227-251.
33. Mejean L., Bicakova-Rocher A., Kolopp M., Villaume C., Levi F., Debry G., Reinberg A., Drouin P. Circadian and ultradian rhythms in blood glucose and plasma insulin of healthy adults. Chronobiol. Int. 1988, 5:227-236.
34. Meltzer H.Y. Dimensions of outcome with clozapine. Br. J. Psychiatry Suppl. 1992, 46-53.
35. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl.) 1989, 99:S68-S72.
36. Meltzer H.Y., Bobo W.V., Lee M.A., Cola P., Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res. 2010, 177:286-293.
37. Mondelli V., Dazzan P., Hepgul N., Di Forti M., Aas M., D'Albenzio A., Di Nicola M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
38. Monti J.M., BaHammam A.S., Pandi-Perumal S.R., Bromundt V., Spence D.W., Cardinali D.P., Brown G.M. Sleep and circadian rhythm dysregulation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 43:209-216.
39. Naheed M., Green B. Focus on clozapine. Curr. Med. Res. Opin. 2001, 17:223-229.
40. Obermeier M., Mayr A., Schennach-Wolff R., Seemuller F., Moller H.J., Riedel M. Should the PANSS be rescaled?. Schizophr. Bull. 2009, 36:455-460.
41. Panda S., Sato T.K., Castrucci A.M., Rollag M.D., DeGrip W.J., Hogenesch J.B., Provencio I., Kay S.A. Melanopsin (Opn4) requirement for normal light-induced circadian phase shifting. Science 2002, 298:2213-2216.
42. Peng Z.W., Chen X.G., Wei Z. Cryptochrome1 maybe a candidate gene of schizophrenia. Med. Hypotheses 2007, 69:849-851.
43. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18:9996-10015.
44. Rao M.L., Gross G., Strebel B., Halaris A., Huber G., Braunig P., Marler M. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol. Psychiatry 1994, 35:151-163.
45. Rao M.L., Strebel B., Halaris A., Gross G., Braunig P., Huber G., Marler M. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia. Psychiatry Res. 1995, 57:21-39.
46. Reick M., Garcia J.A., Dudley C., McKnight S.L. NPAS2: an analog of clock operative in the mammalian forebrain. Science 2001, 293:506-509.
47. Reynolds G.P. The pharmacogenetics of symptom response to antipsychotic drugs. Psychiatry Investig. 2012, 9:1-7.
48. Takao T., Tachikawa H., Kawanishi Y., Mizukami K., Asada T. CLOCK gene T3111C polymorphism is associated with Japanese schizophrenics: a preliminary study. Eur. Neuropsychopharmacol. 2007, 17:273-276.
49. Tuunainen A., Wahlbeck K., Gilbody S.M. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst. Rev. 2000, CD000966.
50. van Nimwegen L.J., Blumer R.M.E., Allick G., Venema H.W., de Haan L., Becker H., van Amelsvoort T., Ackermans M.T., Fliers E., Serlie M.J., Sauerwein H.P. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J. Clin. Endocrinol. Metab. 2008, 93:572-577.
51. Vanelle J.M. Schizophrenia and circadian rhythms. Encephale 2009, 35S:80-83.
52. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol. 2008, 4:189-216.
53. Wirz-Justice A., Werth E., Savaskan E., Knoblauch V., Gasio P.F., Muller-Spahn F. Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2000, 14:212-215.
54. Wirz-Justice A., Haug H.J., Cajochen C. Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs?. Schizophr. Bull. 2001, 27:497-502.
55. Yeragani V.K. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can. J. Psychiatry 1990, 35:128-132.
56. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30:1532-1538.